GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aleafia Health Inc (OTCPK:ALEAF) » Definitions » EV-to-EBITDA
中文

Aleafia Health (Aleafia Health) EV-to-EBITDA : -2.86 (As of Apr. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Aleafia Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aleafia Health's enterprise value is $38.84 Mil. Aleafia Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-13.56 Mil. Therefore, Aleafia Health's EV-to-EBITDA for today is -2.86.

The historical rank and industry rank for Aleafia Health's EV-to-EBITDA or its related term are showing as below:

ALEAF's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 13.88
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Aleafia Health's stock price is $0.0151. Aleafia Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.059. Therefore, Aleafia Health's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Aleafia Health EV-to-EBITDA Historical Data

The historical data trend for Aleafia Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aleafia Health EV-to-EBITDA Chart

Aleafia Health Annual Data
Trend Jan12 Jan13 Jan14 Jan15 Jan16 Oct17 Dec18 Dec19 Dec20 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -11.15 -9.75 -0.73 -3.53

Aleafia Health Quarterly Data
Oct17 Jan18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.88 5.42 -6.87 -3.53

Competitive Comparison of Aleafia Health's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aleafia Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aleafia Health's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aleafia Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aleafia Health's EV-to-EBITDA falls into.



Aleafia Health EV-to-EBITDA Calculation

Aleafia Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=38.837/-13.559
=-2.86

Aleafia Health's current Enterprise Value is $38.84 Mil.
Aleafia Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aleafia Health  (OTCPK:ALEAF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aleafia Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0151/-0.059
=At Loss

Aleafia Health's share price for today is $0.0151.
Aleafia Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.059.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Aleafia Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aleafia Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aleafia Health (Aleafia Health) Business Description

Traded in Other Exchanges
N/A
Address
85 Basaltic Road, Concord, ON, CAN, L4K 1G4
Aleafia Health Inc is a vertically integrated cannabis health and wellness company which owns three cannabis product and cultivation facilities where it produces a diverse portfolio of commercially high-margin derivative products including oils, capsules and sprays. The company operates national network of medical cannabis clinics and has seen over 60,000 patients to date.